The therapeutic potential of duloxetine in prostate cancer-related fatigue  

作　　者：Rita De Sanctis Alessandro Viganò 

机构地区：[1]Department of Medical Oncology and Haematology,Humanitas Clinical and Research Center,IRCCS,20089 Rozzano,Italy [2]Department of Neurology and Psychiatry,Sapienza University,00185 Rome,Italy [3]Department of Anatomy,Histology,Forensic Medicine and Orthopaedics,Sapienza University,00185 Rome,Italy

出　　处：《Journal of Cancer Metastasis and Treatment》2016年第1期64-66,共3页癌症转移与治疗（英文版）

摘　　要：Cancer-related fatigue(CRF)is a common polysymptomatic syndrome with no standard therapy.The authors present the case of a prostate cancer patient in whom,during hormone therapy,disabling CRF and urinary incontinence occurred.CRF was assessed according to the brief fatigue inventory(BFI).The patient received duloxetine,60 mg daily,due to its impact on both CRF and incontinence.After 2 months,the BFI score decreased(from 9 to 2)and urinary incontinence resolved.After duloxetine discontinuation,the patient maintained a low BFI score.The authors conclude that,as a serotonin-noradrenaline reuptake inhibitor,duloxetine could be active on prostate CRF,especially with associated urinary symptoms.Therefore,a pilot placebo-controlled trial with duloxetine to treat prostate CRF may be worthwhile.

关 键 词：DULOXETINE FATIGUE prostate cancer 

分 类 号：R69[医药卫生—泌尿科学]